JP2025515045A5 - - Google Patents

Info

Publication number
JP2025515045A5
JP2025515045A5 JP2024564715A JP2024564715A JP2025515045A5 JP 2025515045 A5 JP2025515045 A5 JP 2025515045A5 JP 2024564715 A JP2024564715 A JP 2024564715A JP 2024564715 A JP2024564715 A JP 2024564715A JP 2025515045 A5 JP2025515045 A5 JP 2025515045A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
stereoisomer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020832 external-priority patent/WO2023215377A1/en
Publication of JP2025515045A publication Critical patent/JP2025515045A/ja
Publication of JP2025515045A5 publication Critical patent/JP2025515045A5/ja
Pending legal-status Critical Current

Links

JP2024564715A 2022-05-04 2023-05-03 神経炎症病態を治療する方法 Pending JP2025515045A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263338328P 2022-05-04 2022-05-04
US63/338,328 2022-05-04
US202263414111P 2022-10-07 2022-10-07
US63/414,111 2022-10-07
US202263424352P 2022-11-10 2022-11-10
US63/424,352 2022-11-10
US202363447432P 2023-02-22 2023-02-22
US63/447,432 2023-02-22
PCT/US2023/020832 WO2023215377A1 (en) 2022-05-04 2023-05-03 Methods of treating neuroinflammatory conditions

Publications (2)

Publication Number Publication Date
JP2025515045A JP2025515045A (ja) 2025-05-13
JP2025515045A5 true JP2025515045A5 (cg-RX-API-DMAC7.html) 2026-05-13

Family

ID=86693083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564715A Pending JP2025515045A (ja) 2022-05-04 2023-05-03 神経炎症病態を治療する方法

Country Status (10)

Country Link
US (1) US20250275976A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515045A (cg-RX-API-DMAC7.html)
KR (1) KR20250005230A (cg-RX-API-DMAC7.html)
CN (1) CN119156217A (cg-RX-API-DMAC7.html)
AU (1) AU2023263997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248640A1 (cg-RX-API-DMAC7.html)
IL (1) IL316281A (cg-RX-API-DMAC7.html)
TW (1) TW202406554A (cg-RX-API-DMAC7.html)
WO (1) WO2023215377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538382A (ja) * 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2021371026A1 (en) * 2020-11-02 2023-06-15 LeonaBio, Inc. Bicyclic compounds and uses thereof for the treatment of diseases
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases

Similar Documents

Publication Publication Date Title
JP2023528623A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2018528261A5 (cg-RX-API-DMAC7.html)
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
JP2018529690A5 (cg-RX-API-DMAC7.html)
JP2024532768A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
JP2018507877A5 (cg-RX-API-DMAC7.html)
JP2016529324A5 (cg-RX-API-DMAC7.html)
JP2016506962A5 (cg-RX-API-DMAC7.html)
JP2015527387A5 (cg-RX-API-DMAC7.html)
JP2011219498A5 (cg-RX-API-DMAC7.html)
JP2020502047A5 (cg-RX-API-DMAC7.html)
JP2016506959A5 (cg-RX-API-DMAC7.html)
JP2015522650A5 (cg-RX-API-DMAC7.html)
JP2011529054A5 (cg-RX-API-DMAC7.html)
JP2016506961A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2015535847A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2022525069A5 (cg-RX-API-DMAC7.html)
PE20090598A1 (es) Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1
JP2006507355A5 (cg-RX-API-DMAC7.html)
JP2019527724A5 (cg-RX-API-DMAC7.html)